Prescription–Event Monitoring in New Zealand

Harrison‐Woolrych, Mira

doi:10.1002/9781118820186.ch23

Cited by 5 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At a meeting of pharmacovigilance experts and specialists in epidemiology, HIV and TB participants proposed cohort event monitoring (CEM) and targeted spontaneous reporting (TSR) as having good potential for use in monitoring the safety of medicines used long-term in populations with specified diseases. CEM involves reporting of all adverse events occurring in a cohort of patients identified as having received treatment with a specified drug (as occurs, for example, in Prescription Event Monitoring in the UK [ 8 ] or the Intensive Medicines Monitoring Programme in New Zealand [ 9 ]). TSR focuses on capturing ADRs in a well defined group of patients on treatment, based on the premise that patients, whose condition is repeatedly being followed-up at the same health facility during long-term treatment, should be routinely monitored for suspected ADRs [ 10 ].…”

Section: Project Activities and Resultsmentioning

confidence: 99%

The Monitoring Medicines Project: A Multinational Pharmacovigilance and Public Health Project

Pal¹,

Olsson

Brown³

2015

Drug Saf

View full text Add to dashboard Cite

The Monitoring Medicines project (MM), funded by the FP-7 EU framework, was carried out between 2009 and 2013 by a consortium of 11 partners. The objectives were to support and strengthen consumer reporting of adverse drug reactions (ADRs); expand the role and scope of national pharmacovigilance centres concerning medication errors; promote improved use of pharmacovigilance data; and develop methods to complement spontaneous reporting. The work was organised into four themes: patient reporting; medication errors; drug dependence, counterfeit and substandard medicines and clinical risk estimation; and active and targeted spontaneous pharmacovigilance. MM differed from some other major pharmacovigilance initiatives by having participants from developing countries in Asia and Africa and in leaning towards public health and communicable diseases. MM brought together stakeholders including WHO, drug regulators, pharmacovigilance centres, consumers, public health and disease specialists and patient safety networks. Resources and methodologies developed directly by, or with support from, MM include electronic systems/tools for consumer ADR reporting and cohort event monitoring; publication by WHO of handbooks on consumer reporting, medication errors and pharmacovigilance for TB medicines; methodologies for detecting drug dependence and substandard or counterfeit medicines in ADR databases; and a database on HIV treatment risks with a risk assessment tool. MM enabled stakeholders to achieve more than if they had worked alone in pursuit of patient safety.

show abstract

Section: Project Activities and Resultsmentioning

confidence: 99%

The Monitoring Medicines Project: A Multinational Pharmacovigilance and Public Health Project

Pal¹,

Olsson

Brown³

2015

Drug Saf

View full text Add to dashboard Cite

show abstract

“…In December 2013 the IMMP closed due to insufficient funding. Now, the only type of post-marketing surveillance for IUDs (and other contraceptive products) in NZ and most other countries are spontaneous reporting programmes, which do not collect denominator data and are therefore unable to calculate frequency rates of adverse events (Harrison-Woolrych 2014).…”

Section: Contraceptive Devices For Womenmentioning

confidence: 99%